597 filings
8-K
OGEN
Oragenics Inc
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
10-K
2023 FY
OGEN
Oragenics Inc
Annual report
29 Mar 24
4:16pm
8-K
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
8-K
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
424B5
OGEN
Oragenics Inc
29 Feb 24
Prospectus supplement for primary offering
4:41pm
8-K
18hz95g
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
p2l0u28sdlsv
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
FWP
86mox
27 Feb 24
Free writing prospectus
5:09pm
424B5
vnr4yn8b
27 Feb 24
Prospectus supplement for primary offering
5:04pm
8-K
yvf m9y1vkc
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
vmm3g
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
24fyr83a514a v65
5 Feb 24
Other Events
8:00am
8-K
ljmtucwmt5lxh2td
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
8-K
udb2p8 jt
16 Jan 24
Other Events
9:10am
FWP
5srsyzjxmtvv b96jicx
16 Jan 24
Free writing prospectus
9:08am
424B5
unjtcpc ekhdtbdc
16 Jan 24
Prospectus supplement for primary offering
9:04am
S-8
ek51y beey9bx
10 Jan 24
Registration of securities for employees
4:37pm
8-K
xd5b1 tkj
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
7xhcz0m6 ad4jc0
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
woc3uhzaldacu09d
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm